Healthy Skepticism Library item: 9951
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Wang YR, Pauly MV, Lin YA.
Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.
Am J Manag Care 2003 Oct; 9:(10):686-96
http://www.ncbi.nlm.nih.gov/pubmed/14572179
Abstract:
BACKGROUND: Market penetration of HMOs affect physician practice styles for non-HMO patients. OBJECTIVE: To study the impact of a restrictive Medicaid drug formulary on prescribing patterns for other patients, ie, so-called spillover effects. DESIGN: A before-and-after, 3-state comparison study. EVENT: On January 1, 2001, Maine’s Medicaid program implemented a restrictive drug formulary for the proton pump inhibitor class, with pantoprazole as the only preferred drug. MAIN OUTCOME MEASURE: The Medicaid and non-Medicaid market shares of pantoprazole in Maine (vs New Hampshire and Vermont and among Maine physicians with different Medicaid share of practice. RESULTS: After 3 months, the market share of pantoprazole in Maine (vs 2 control states) increased 79% among Medicaid prescriptions (vs 1%-2%), 10% among cash prescriptions (vs 3%), and 7% among other third-party payer prescriptions (vs 1%). The market shares increased more among Maine physicians with a higher Medicaid share of practice (high vs middle vs low [market]: 16% vs 8% vs 5% [cash]; 11% vs 5% vs 4% [other third-party payers]). Linear regression results indicate that practicing medicine in Maine leads to a 72% increase in pantoprazole share among Medicaid prescriptions (P < .001). In addition, for each 10% Medicaid share of practice in Maine, the share of pantoprazole increases 1.8% among cash prescriptions (P = .01) and 1.4% among other third-party payer prescriptions (P < .001). CONCLUSIONS: Maine’s Medicaid drug formulary generated spillover effects in cash and other third-party payer markets, with somewhat stronger effects in the cash market.
Keywords:
2-Pyridinylmethylsulfinylbenzimidazoles
Benzimidazoles/economics
Benzimidazoles/therapeutic use*
Drug Utilization/economics*
Drug Utilization/trends
Enzyme Inhibitors/economics
Enzyme Inhibitors/therapeutic use*
Formularies*
Gastroesophageal Reflux/drug therapy*
Health Care Sector/statistics & numerical data
Health Care Sector/trends*
Health Maintenance Organizations/economics*
Humans
Insurance, Pharmaceutical Services
Maine
Medicaid*
Omeprazole/analogs & derivatives
Physician's Practice Patterns/economics
Physician's Practice Patterns/trends
Proton Pumps/antagonists & inhibitors*
Proton Pumps/classification
Proton Pumps/economics
State Health Plans*
Sulfoxides/economics
Sulfoxides/therapeutic use*
United States
